Rank #1622TARS

Tarsus Pharmaceuticals, Inc.

$65.54

3.59% (Daily)

Market Cap

$2.78B

Revenue

$366.10M

Rank by MCap

#1622

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Bobak R. Azamian M.D.

Headquarters

Irvine, CA

Employees

323

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and commun...